Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Prepaid and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use asset
Deferred offering costs
Other assets
Total assets
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
Accrued research and development
Other accrued liabilities
Operating lease liability, current portion
Total current liabilities
Operating lease liability, net of current portion
Other long-term liabilities
Total liabilities
Convertible preferred stock
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Total convertible preferred stock
Stockholders' equity:
Common stock, $0.001 par value; 250,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 36,375,671 shares (comprised of 27,579,947 shares of common stock and 8,795,724 shares of non-voting common stock) and 36,290,292 shares (comprised of 25,947,572 shares of common stock and 10,342,720 shares of non-voting common stock) issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support